These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 19648825

  • 21. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [Abstract] [Full Text] [Related]

  • 22. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [Abstract] [Full Text] [Related]

  • 23. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 24. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS, Magerle M, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckman K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, Preusser M, Birner P.
    APMIS; 2013 Dec 01; 121(12):1144-52. PubMed ID: 23756255
    [Abstract] [Full Text] [Related]

  • 25. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
    Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG.
    Lung Cancer; 2011 Nov 01; 74(2):293-9. PubMed ID: 21440951
    [Abstract] [Full Text] [Related]

  • 26. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep 01; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 27. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
    Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ, Dunn SE.
    Oncogene; 2009 Mar 19; 28(11):1421-31. PubMed ID: 19151767
    [Abstract] [Full Text] [Related]

  • 28. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 29. Prognostic significance of overexpressed matrix metalloproteinase-2, mouse-double minute: 2 homolog and epidermal growth factor receptor in non-small cell lung cancer.
    Jiang LY, Bi R, Ding FB, Wang MS, Mei J, He Y.
    J BUON; 2016 Dec 01; 21(2):341-8. PubMed ID: 27273943
    [Abstract] [Full Text] [Related]

  • 30. C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
    CsToth I, Anthoine G, Berghmans T, Mascaux C, Paesmans M, Sculier JP, Meert AP.
    Anticancer Res; 2011 Jan 01; 31(1):281-5. PubMed ID: 21273611
    [Abstract] [Full Text] [Related]

  • 31. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
    Hirsch FR, Varella-Garcia M, Cappuzzo F.
    Oncogene; 2009 Aug 01; 28 Suppl 1():S32-7. PubMed ID: 19680294
    [Abstract] [Full Text] [Related]

  • 32. Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy.
    Tsakiridis T, Cutz JC, Singh G, Hirte H, Okawara G, Corbett T, Sur R, Cai W, Whelan T, Wright JR.
    J Thorac Oncol; 2008 Jul 01; 3(7):716-22. PubMed ID: 18594316
    [Abstract] [Full Text] [Related]

  • 33. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers.
    Harada M, Kotake Y, Ohhata T, Kitagawa K, Niida H, Matsuura S, Funai K, Sugimura H, Suda T, Kitagawa M.
    Genes Cells; 2014 Jun 01; 19(6):504-16. PubMed ID: 24774443
    [Abstract] [Full Text] [Related]

  • 34. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
    Cheng TL, Chang MY, Huang SY, Sheu CC, Kao EL, Cheng YJ, Chong IW.
    Chest; 2005 Sep 01; 128(3):1453-60. PubMed ID: 16162743
    [Abstract] [Full Text] [Related]

  • 35. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB, Zheng Z, Song L, Cantor A, Bepler G.
    Clin Cancer Res; 2005 Dec 01; 11(23):8288-94. PubMed ID: 16322287
    [Abstract] [Full Text] [Related]

  • 36. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, Horinouchi H, Nagashima M, Sekiguchi M, Tamura T.
    Lung Cancer; 2015 Jun 01; 88(3):275-81. PubMed ID: 25891541
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N, Uchida Y.
    Anticancer Res; 2013 Nov 01; 33(11):5083-9. PubMed ID: 24222153
    [Abstract] [Full Text] [Related]

  • 39. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK.
    J Clin Oncol; 2005 Apr 10; 23(11):2493-501. PubMed ID: 15710947
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.